Affinity DataKi: 236nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.05E+3nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 8.03E+3nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 3.34E+4nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 4.35E+4nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
Affinity DataKi: >5.00E+5nMAssay Description:Inhibition of human thymidine phosphorylase by continuous spectrophotometric assayMore data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: <100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Dart Neuroscience (Cayman)
US Patent
Dart Neuroscience (Cayman)
US Patent
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair